v3.26.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 11, 2025
Nov. 25, 2024
May 31, 2025
Apr. 30, 2025
Jan. 31, 2025
Mar. 31, 2024
Jan. 31, 2024
Jul. 31, 2023
Dec. 31, 2025
Dec. 31, 2024
Jun. 26, 2023
Loss Contingencies [Line Items]                      
Cancellation of stock options and issuance of common stock   $ 534,800 $ 554,586 $ 554,586         $ 1,512,994    
Repayments of related party debt                 531,000  
Outstanding balance of development agreement liability                 $ 285,000 $ 1,285,000  
Eat Well Investment Group Inc [Member]                      
Loss Contingencies [Line Items]                      
Cancellation of stock options and issuance of common stock         $ 8,500,000            
Eat Well Investment Group Inc [Member] | Legacy Note [Member]                      
Loss Contingencies [Line Items]                      
Unpaid principal and accrued interest         1,150,000            
Cash consideration         350,000            
Eat Well Investment Group Inc [Member] | Ten Promissory Note [Member]                      
Loss Contingencies [Line Items]                      
Unpaid principal and accrued interest         $ 755,000            
Series B Preferred Stock [Member]                      
Loss Contingencies [Line Items]                      
Preferred stock, par value                 $ 0.00001 $ 0.00001 $ 0.00001
Amended and Restated Agreement and Plan of Merger [Member] | Series B Preferred Stock [Member]                      
Loss Contingencies [Line Items]                      
Stock issued, acquisition             15,759 306,855      
Preferred stock, par value               $ 0.00001      
Common stock conversion ratio               Company’s common stock at a conversion ratio of 100-1.      
Amended and Restated Agreement and Plan of Merger [Member] | Series B Preferred Stock [Member] | Eat Well Investment Group Inc [Member]                      
Loss Contingencies [Line Items]                      
Stock issued, acquisition         11,643.84            
Exclusive License And Commercial Agreements [Member]                      
Loss Contingencies [Line Items]                      
Total gross amount           $ 1,285,000          
Contract termination claims description           the full $1,285,900 has not been repaid within two years of the earlier of (i) commercial launch or (ii) 120 days from FDA approval, then interest will accrue prospectively at a rate of 8% annually on the unpaid balance. Accordingly, Scienture recorded a $1,285,000 development agreement liability at inception.          
Repayments of related party debt           $ 489,848          
Principal portion of debt repaid           400,000          
Accrued Interest           $ 89,848          
Outstanding balance of development agreement liability                 $ 885,000 $ 1,285,000  
Current portion of contract termination liability                 600,000  
Noncurrent portion of contract termination liability                 $ 285,000 $ 1,285,000  
Disputed value $ 1,285,000